Moderna’s Bancel Dismisses GSK And Sanofi Challenge In mRNA Vaccines
New Entrants Will Find “It’s Much Harder Than They Think”
Executive Summary
Under pressure to show Moderna can grow the company’s mRNA vaccines portfolio beyond COVID-19, CEO Stéphane Bancel has talked down his rivals in the field.
You may also be interested in...
Moderna Looks To Catch Up In COVID-19 For Kids, While Still Branching Out In Other Areas
The company hopes to expand Spikevax’s reach beyond the current approved population while also looking to take the lead in mRNA vaccines in other diseases.
Coronavirus Update: AbbVie Jumps Into Antiviral Research With Scripps Pact
AbbVie is taking the plunge into the highly competitive area of antiviral research through a new alliance, while Pfizer files for US approval of an additional mRNA booster shot and a vaccines group is unhappy about planned IP waivers.
Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR
Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.